Yokneam Illit. Founded 2008 (as Invasix) by Moshe Mizrahy and Dr. Michael Kreindel — Syneron Medical alumni. NASDAQ: INMD. RFAL + fractional RF platforms: Morpheus8, BodyTite, Evolve X, Empower. FY 2025 guidance $365-375M. Q3 2025 GAAP gross margin 78%.
Israeli Health & Biotech | Olam.business
InMode Ltd. (NASDAQ: INMD) is an Israeli medical-aesthetics platform headquartered in Yokneam Illit, co-founded in 2008 by Moshe Mizrahy and Dr. Michael Kreindel — both prior co-founders of Syneron Medical, the earlier Israeli aesthetic-laser company. Formerly Invasix Ltd. until a November 2017 rename, InMode built its market position on proprietary radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency (RF) technology. Ten platforms; 22 technological innovations, seven patented. Full-year 2025 revenue guidance: $365-375 million; Q3 2025 GAAP gross margin 78 percent.
Snapshot
| Location | Yokneam Illit, Israel |
| Founded | 2008 (as Invasix Ltd.; renamed InMode Ltd. November 2017) |
| Founders | Moshe Mizrahy (Chairman & CEO); Dr. Michael Kreindel (CTO) |
| Public listing | NASDAQ: INMD (IPO 2019) |
| Core technology | Proprietary RFAL; deep subdermal fractional RF |
| Named platforms | Morpheus8, Evolve X, Empower, BodyTite, FaceTite, AccuTite, Contoura, Optimas, Fractora |
| FY 2025 revenue guidance | $365-375 million |
The 2008 Founding
InMode's institutional lineage runs through Syneron Medical. Moshe Mizrahy co-founded Syneron and served as CEO; Dr. Michael Kreindel co-founded Syneron and served as CTO from 2001 to 2007. In 2008, the two founded Invasix with a thesis that radiofrequency would be the dominant energy modality for the next generation of minimally invasive aesthetic procedures.
The RF Platform
RFAL is InMode's proprietary invasive-mode technology: an RF probe passed under the skin to simultaneously liquefy fat, coagulate soft tissue, and induce dermal contraction. Deep subdermal fractional RF is the operating basis of Morpheus8 — the most-searched InMode brand. Evolve X automates body-shaping and skin-tightening. Empower (launched August 2021) extended the RF technology into women's health.
Revenue Architecture
InMode combines high-margin capital-equipment sales with growing recurring-revenue streams from consumables and service contracts. Q3 2025: $93.2 million total, consumables and service $19.9 million (+26% YoY). Non-GAAP gross margin guidance for FY 2025: 78-80 percent.
Related Olam Coverage
The Olam Editorial Team